Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 4/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | IDO1 | P14902 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylserotonin SCHEMBL422165 | 0.87 | SPR (1.00) | SPRKDM4EALDH1A1NPSR1CYP2D6 | |
| SCHEMBL13645692 | 0.87 | SPR (0.76) | SPRKDM4EALDH1A1NPSR1CYP2D6 | |
| Acetylserotonin SCHEMBL30295379 | 0.87 | SPR (1.00) | SPRKDM4EALDH1A1NPSR1CYP2D6 | |
| SCHEMBL29679229 | 0.87 | SPR (0.76) | SPRKDM4EALDH1A1NPSR1CYP2D6 | |
| Acetylserotonin SCHEMBL29375184 | 0.87 | SPR (1.00) | SPRKDM4EALDH1A1NPSR1CYP2D6 | |
| SCHEMBL25137286 | 0.86 | TRPV1 (0.76) | SPRKDM4EALDH1A1NPSR1CYP2D6 | |
| Acetylserotonin SCHEMBL31488730 | 0.86 | SPR (0.97) | SPRKDM4EALDH1A1NPSR1CYP2D6 | |
| SCHEMBL2271234 | 0.86 | SPR (0.74) | SPRKDM4EALDH1A1NPSR1CYP2D6 | |
| Acetylserotonin SCHEMBL29669245 | 0.86 | SPR (0.97) | SPRKDM4EALDH1A1NPSR1CYP2D6 | |
| Bufobutanoic Acid SCHEMBL22804772 | 0.85 | TRPV1 (0.71) | SPRKDM4EALDH1A1NPSR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117049994-A | Preparation method of 5-methoxy tryptamine | 河北维达康生物科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-20190345143-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty Ltd (AU) | 2019-11-14 | — | — | US | disclosed |
| EP-3555071-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018107201-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty Ltd (AU) | 2018-06-21 | — | — | WO | disclosed |
| CN-106008466-A | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 艾伯维公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-102307622-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-103097352-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-05-08 | — | — | CN | disclosed |
| EP-2507211-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068560-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345143-A1 | HEPARANASE INHIBITORS AND USE THEREOF | HPSE, HEXD, ENGASE | SPR 418/4885KDM4E 2390/4885ALDH1A1 1394/4885 |
| US-11787783-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | SPR 418/4885KDM4E 2390/4885ALDH1A1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.